Literature DB >> 18503828

A BCR-JAK2 fusion gene as the result of a t(9;22)(p24;q11) in a patient with acute myeloid leukemia.

Gabriella Cirmena1, Stefania Aliano, Giuseppina Fugazza, Roberto Bruzzone, Anna Garuti, Renata Bocciardi, Andrea Bacigalupo, Roberto Ravazzolo, Alberto Ballestrero, Mario Sessarego.   

Abstract

We report the occurrence of a BCR-JAK2 fusion gene in a case of acute myeloid leukemia (AML) resulting from a t(9;22)(p24;q11) translocation as the sole cytogenetic abnormality. The BCR-JAK2 fusion gene has the same breakpoint in BCR as is found in the BCR/ABL p210. The chimeric gene is the result of a reciprocal translocation between chromosomes 9 and 22, which implies a double break on chromosome 9; this has allowed generating an in-frame fusion transcript. Previously, BCR-JAK2 rearrangement was observed in a single case with atypical chronic myelogenous leukemia (CML), but in that case the breakpoint in the BCR was different. (c) 2008 Elsevier Inc.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18503828     DOI: 10.1016/j.cancergencyto.2008.02.005

Source DB:  PubMed          Journal:  Cancer Genet Cytogenet        ISSN: 0165-4608


  17 in total

Review 1.  Genomic profiling of B-progenitor acute lymphoblastic leukemia.

Authors:  Charles G Mullighan
Journal:  Best Pract Res Clin Haematol       Date:  2011-11-06       Impact factor: 3.020

Review 2.  Myelodysplastic syndrome with t(9;22)(p24;q11.2), a BCR-JAK2 fusion: case report and review of the literature.

Authors:  Bulent Kantarcioglu; Isik Kaygusuz-Atagunduz; Ant Uzay; Tayfur Toptas; Tulin Firatli Tuglular; Mahmut Bayik
Journal:  Int J Hematol       Date:  2015-04-02       Impact factor: 2.490

3.  Jak/STAT pathways in cytokine signaling and myeloproliferative disorders: approaches for targeted therapies.

Authors:  Shashidhar S Jatiani; Stacey J Baker; Lewis R Silverman; E Premkumar Reddy
Journal:  Genes Cancer       Date:  2010-10

Review 4.  A structure-function perspective of Jak2 mutations and implications for alternate drug design strategies: the road not taken.

Authors:  K Gnanasambandan; P P Sayeski
Journal:  Curr Med Chem       Date:  2011       Impact factor: 4.530

5.  Genetic alterations activating kinase and cytokine receptor signaling in high-risk acute lymphoblastic leukemia.

Authors:  Kathryn G Roberts; Ryan D Morin; Jinghui Zhang; Martin Hirst; Yongjun Zhao; Xiaoping Su; Shann-Ching Chen; Debbie Payne-Turner; Michelle L Churchman; Richard C Harvey; Xiang Chen; Corynn Kasap; Chunhua Yan; Jared Becksfort; Richard P Finney; David T Teachey; Shannon L Maude; Kane Tse; Richard Moore; Steven Jones; Karen Mungall; Inanc Birol; Michael N Edmonson; Ying Hu; Kenneth E Buetow; I-Ming Chen; William L Carroll; Lei Wei; Jing Ma; Maria Kleppe; Ross L Levine; Guillermo Garcia-Manero; Eric Larsen; Neil P Shah; Meenakshi Devidas; Gregory Reaman; Malcolm Smith; Steven W Paugh; William E Evans; Stephan A Grupp; Sima Jeha; Ching-Hon Pui; Daniela S Gerhard; James R Downing; Cheryl L Willman; Mignon Loh; Stephen P Hunger; Marco A Marra; Charles G Mullighan
Journal:  Cancer Cell       Date:  2012-08-14       Impact factor: 31.743

Review 6.  Polycythemia as rare secondary direct manifestation of acromegaly: management and single-centre epidemiological data.

Authors:  Gabriele Zoppoli; Federico Bianchi; Andrea Bruzzone; Alessandro Calvia; Caterina Oneto; Caterina Passalia; Enrico Balleari; Davide Bedognetti; Elena Ponomareva; Elena Nazzari; Lara Castelletti; Lucio Castellan; Francesco Minuto; Riccardo Ghio; Diego Ferone
Journal:  Pituitary       Date:  2012-06       Impact factor: 4.107

7.  A Non-ATP-Competitive Dual Inhibitor of JAK2 and BCR-ABL Kinases: Elucidation of a Novel Therapeutic Spectrum Based on Substrate Competitive Inhibition.

Authors:  Shashidhar S Jatiani; Stephen C Cosenza; M V Ramana Reddy; Ji Hee Ha; Stacey J Baker; Ajoy K Samanta; Matthew J Olnes; Loretta Pfannes; Elaine M Sloand; Ralph B Arlinghaus; E Premkumar Reddy
Journal:  Genes Cancer       Date:  2010-04

Review 8.  Janus kinases in immune cell signaling.

Authors:  Kamran Ghoreschi; Arian Laurence; John J O'Shea
Journal:  Immunol Rev       Date:  2009-03       Impact factor: 12.988

Review 9.  A comprehensive review of pacritinib in myelofibrosis.

Authors:  Srdan Verstovsek; Rami S Komrokji
Journal:  Future Oncol       Date:  2015-09-14       Impact factor: 3.404

10.  JAK Kinases in Health and Disease: An Update.

Authors:  Arian Laurence; Marko Pesu; Olli Silvennoinen; John O'Shea
Journal:  Open Rheumatol J       Date:  2012-09-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.